The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog - PubMed
. 1976 Jun;197(3):517-32.
- PMID: 945347
The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog
W R Martin et al. J Pharmacol Exp Ther. 1976 Jun.
Abstract
Three different syndromes produced by congeners of morphine have been identified in the nondependent chronic spinal dog. These syndromes have been attributed to interaction of agonists with three distinguishable receptors (mu, kappa and sigma). Morphine is the prototype agonist for the mu receptor, ketocyclazocine for the kappa receptor and SKF-10,047 for the sigma receptor. The morphine syndrome (mu) in the dog is characterized by miosis, bradycardia, hypothermia, a general depression of the nociceptive responses and indifference to environmental stimuli. Ketocyclazocine (kappa) constricts pupils, depresses the flexor reflex and produces sedation but does not markedly alter pulse rate or the skin twitch reflex. SKF-10,047 (sigma), in contrast to morphine and ketocyclazocine, causes mydriasis, tachypnea, tachycardia and mania. The effects of these three drugs can be antagonized by the pure antagonist naltrexone, indicating that they are agonists. Further, chronic administration of morphine, ketocyclazocine and SKF-10,047 induces tolerance to their agonistic effects. Morphine suppresses abstinence in morphine-dependent dogs while ketocyclazocine does not. Ketocyclazocine at best precipitated only a liminal abstinence syndrome in the morphine-dependent dog, indicating that it had little affinity for the morphine receptor. Ketocyclazocine thus appears to be a selective agonist at the kappa receptor. Further, it has been shown that buprenorphine is a partial agonist of the mu type which both suppressed and precipitated abstinence in the morphine-dependent dog while morphine and propoxyphene are stronger agonists. Apomorphine and SKF-10,047 produce similar pharmacologic effects suggesting that sigma activity may involve a dopaminergic mechanism.
Similar articles
-
Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo.
Kumor KM, Haertzen CA, Johnson RE, Kocher T, Jasinski D. Kumor KM, et al. J Pharmacol Exp Ther. 1986 Sep;238(3):960-8. J Pharmacol Exp Ther. 1986. PMID: 3018228 Clinical Trial.
-
Sigma effects of nalorphine in the chronic spinal dog.
Gilbert PE, Martin WR. Gilbert PE, et al. Drug Alcohol Depend. 1976 Oct;1(6):373-6. doi: 10.1016/0376-8716(76)90001-6. Drug Alcohol Depend. 1976. PMID: 189982
Cited by
-
Fallica AN, Pittalà V, Modica MN, Salerno L, Romeo G, Marrazzo A, Helal MA, Intagliata S. Fallica AN, et al. J Med Chem. 2021 Jun 24;64(12):7926-7962. doi: 10.1021/acs.jmedchem.0c02265. Epub 2021 Jun 2. J Med Chem. 2021. PMID: 34076441 Free PMC article. Review.
-
Kronenberg E, Weber F, Schepmann D, Wünsch B. Kronenberg E, et al. RSC Med Chem. 2020 Dec 9;12(2):237-244. doi: 10.1039/d0md00307g. eCollection 2021 Mar 4. RSC Med Chem. 2020. PMID: 34046612 Free PMC article.
-
The sigma-1 receptor: a regulator of cancer cell electrical plasticity?
Crottès D, Guizouarn H, Martin P, Borgese F, Soriani O. Crottès D, et al. Front Physiol. 2013 Jul 16;4:175. doi: 10.3389/fphys.2013.00175. eCollection 2013. Front Physiol. 2013. PMID: 23882221 Free PMC article.
-
PD117302: a selective agonist for the kappa-opioid receptor.
Clark CR, Birchmore B, Sharif NA, Hunter JC, Hill RG, Hughes J. Clark CR, et al. Br J Pharmacol. 1988 Mar;93(3):618-26. doi: 10.1111/j.1476-5381.1988.tb10319.x. Br J Pharmacol. 1988. PMID: 2836012 Free PMC article.
-
Siniscalchi A, Cristofori P, Veratti E. Siniscalchi A, et al. Naunyn Schmiedebergs Arch Pharmacol. 1987 Oct;336(4):425-9. doi: 10.1007/BF00164877. Naunyn Schmiedebergs Arch Pharmacol. 1987. PMID: 3431597
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases
Research Materials